Shots:
There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United StatesÂ
Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity Â
Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
Shots
To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Â
Continuing the series for the Disease of the Month, PharmaShots brings a condensed report on Pancreatic CancerÂ
November 16th is observed as World Pancreatic Cancer…

